NEWS

WIRES

OTHER

ViRexx President Interviewed by the Zangani Investor Community

ViRexx Medical Corp. (TSX:VIR) (AMEX: REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B and C and embolotherapy treatments for tumors, announced today that the Company's President, Marc Canton, was interviewed on April 27, 2006 by the Zangani Investor Community.

During the interview, Marc Canton discusses the recent Health Canada approval of the Clinical Trial Application to initiate a Phase I trial for the Company's lead Chimigen(TM) vaccine, HepaVaxx B. Health Canada approval provides ViRexx with the opportunity to commence the first human test of the Company's recombinant protein technology platform. Mr. Canton also discusses the preclinical results, which demonstrated a strong safety profile, and potential licensing and partnering strategies for HepaVaxx B.

To access the interview, please visit the Zangani Investor Community at: www.zangani.com/virexx/2006-0428-rex">www.zangani.com/virexx/2006-0428-rex. The interview is also available via Podcast at www.zangani.com or through the itunes music store.

HepaVaxx B

HepaVaxx B vaccine consists of a recombinant chimeric molecule containing a hepatitis B viral antigen and a portion of a murine monoclonal antibody. The molecule is designed to target dendritic cells, which play a significant role in antigen presentation and initiation of an immune response. In preclinical testing, HepaVaxx B has produced both cellular and humoral immune responses. ViRexx believes that the development of humoral and cellular responses may be effective in clearing the virus from patients with chronic hepatitis B infection.

About ViRexx Medical Corp.

ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of certain cancers and specified chronic viral infections. ViRexx's most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B and solid tumors.

ViRexx's lead product candidate, OvaRex® MAb, a therapy for the treatment of late-stage ovarian cancer, is currently the subject of two Phase III clinical trials being funded by ViRexx's licensing partner Unither Pharmaceuticals, Inc., a subsidiary of United Therapeutics Corporation. For additional information about ViRexx, please see www.virexx.com.

About Zangani

Zangani is an outsourced IR and Business Development firm that provides information to investors on small cap and micro cap companies through a multi-media approach. It provides clients with an array of products, including community forums and webcasting. For more information please visit their website at http://www.zangani.com

This news release contains certain forward-looking statements that reflect the current views and/or expectations of the Company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

Distributed by Market Wire